MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$3,940K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from the 2026 term loan...
Loss on debt extinguishment
Accrued expenses and other liabi...
Others
Negative Cash Flow Breakdown
Repayment of the 2023 term loan
Purchases of marketable securiti...
Supplies
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-637
-510
81,957
24,325
Depreciation and amortization
6,538
5,065
4,291
4,870
Stock-based compensation expense
22,219
15,872
13,367
13,655
Non-cash operating lease expense
1,439
1,323
1,262
1,387
Amortization of debt discounts
299
2,624
605
2,463
Changes in fair value of financial instruments
0
0
-1
-2,081
Loss on debt extinguishment
-25,232
-
-1,965
0
Other
241
-214
-428
443
Accounts receivable
26,372
-21,623
91,021
-24,192
Supplies
48,309
13,328
9,606
8,523
Prepaid expenses and other current assets
-895
1,554
345
2,540
Other assets
924
-153
-374
660
Accounts payable
23,261
16,371
12,231
729
Accrued expenses and other liabilities
25,077
-14,977
29,271
889
Net cash provided by (used in) operating activities
28,477
32,876
44,780
62,425
Maturities of marketable securities
-
-
0
0
Sale of marketable securities
1,874
-
-
-
Purchases of marketable securities
101,991
-
0
-
Purchases of property and equipment
-
10,342
5,090
7,095
Capitalized software and purchases of property and equipment
32,417
-
-
-
Net cash used in investing activities
-122,192
-10,342
-5,090
-7,095
Payments made on finance lease obligations
42
40
39
23
Proceeds from exercise of stock options
741
920
3,862
1,151
Payment of taxes withheld from net settlement of exercised options and vested rsus
5,264
56
333
16,560
Payment of deferred offering costs
0
0
0
5,665
Proceeds from the 2023 term loan, net of issuance costs
-
-
0
0
Repurchase of common stock
21,361
0
91
0
Repayment of the 2023 term loan
406,307
-
0
-
Proceeds from the 2026 term loan, net of issuance costs
393,500
-
-
-
Payment of third-party debt issuance costs
1,107
-
0
-
Proceeds from share purchases under employee stock purchase plan
2,937
-
-
-
Issuance of series e and f preferred stock, net of issuance costs-Series EPreferred Stock
0
-
0
0
Issuance of series e and f preferred stock, net of issuance costs-Series FPreferred Stock
0
-
0
0
Issuance of the 2025 convertible notes, net of issuance costs
0
-
0
0
Issuance of the 2025 warrants
0
-
0
0
Payments of the 2023 term loan amendment fee
0
-
0
0
Proceeds from initial public offering, net of underwriting discounts and commissions
0
-
0
0
Net cash provided by (used in) financing activities
-36,903
824
3,399
-21,097
Effect of exchange rate changes on cash, cash equivalents, and restricted cash
-27
-10
-29
62
Net increase (decrease) in cash, cash equivalents, and restricted cash
-130,645
23,348
43,060
34,295
Cash, cash equivalents, and restricted cash at beginning of period
823,390
800,042
756,982
68,028
Cash, cash equivalents, and restricted cash at end of period
692,745
-
-
-
Cash, cash equivalents, and restricted cash
690,915
-
-
-
Restricted cash included in other long-term assets
1,830
-
-
-
Total cash, cash equivalents, and restricted cash
692,745
823,390
800,042
756,982
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Loss on debt
extinguishment
-$25,232K
(-40.73%↓ Y/Y)
Accrued expenses and
other liabilities
$25,077K
(234.24%↑ Y/Y)
Accounts payable
$23,261K
(1308.36%↑ Y/Y)
Stock-based compensation
expense
$22,219K
(-48.31%↓ Y/Y)
Depreciation and
amortization
$6,538K
(-51.40%↓ Y/Y)
Non-cash operating lease
expense
$1,439K
(-50.99%↓ Y/Y)
Prepaid expenses and
other current assets
-$895K
(-139.51%↓ Y/Y)
Amortization of debt
discounts
$299K
(-96.92%↓ Y/Y)
Net cash provided by
(used in) operating...
$28,477K
(218.41%↑ Y/Y)
Canceled cashflow
$76,483K
Net increase
(decrease) in cash, cash...
-$130,645K
(-119.96%↓ Y/Y)
Canceled cashflow
$28,477K
something is missing
$10,342K
Sale of marketable
securities
$1,874K
Proceeds from the 2026
term loan, net of...
$393,500K
Proceeds from share
purchases under employee...
$2,937K
Proceeds from exercise of
stock options
$741K
(-71.76%↓ Y/Y)
Supplies
$48,309K
(1743.15%↑ Y/Y)
Accounts receivable
$26,372K
(171.20%↑ Y/Y)
Other assets
$924K
(376.65%↑ Y/Y)
Net loss
-$637K
(99.63%↑ Y/Y)
Other
$241K
(119.58%↑ Y/Y)
Net cash used in
investing activities
-$122,192K
(-2898.58%↓ Y/Y)
Net cash provided by
(used in) financing...
-$36,903K
(-105.41%↓ Y/Y)
Canceled cashflow
$12,216K
Canceled cashflow
$397,178K
Effect of exchange rate
changes on cash, cash...
-$27K
(-127.84%↓ Y/Y)
Purchases of marketable
securities
$101,991K
Capitalized software and
purchases of property and...
$32,417K
Repayment of the 2023 term
loan
$406,307K
Repurchase of common stock
$21,361K
(96995.45%↑ Y/Y)
Payment of taxes
withheld from net...
$5,264K
(217.49%↑ Y/Y)
Payment of third-party
debt issuance costs
$1,107K
Payments made on finance
lease obligations
$42K
(-4.55%↓ Y/Y)
Buy us a coffee
TN0277-v12_How-To-Order-1(1)
Caris Life Sciences, Inc. (CAI)
TN0277-v12_How-To-Order-1(1)
Caris Life Sciences, Inc. (CAI)